Key Takeaways
- Retatrutide is investigational and not FDA-approved as of July 2026 — no confirmed approval date exists yet.
- Eli Lilly and Company anticipates submitting a New Drug Application (NDA) to the FDA in Q4 2026.
- Standard FDA review takes about 10 months from acceptance; a priority review, if granted, would take about 6 months.
- The projected PDUFA decision date (the FDA’s target date for a ruling) falls in late 2027.
- If approved, commercial launch is projected for Q1–Q2 2028 — but every step in this timeline remains subject to change based on trial outcomes and regulatory review.
Retatrutide’s Regulatory Status Right Now
Before diving into projected dates, it’s essential to be clear about where things stand today. As of July 2026, retatrutide (developer code LY3437943) is not approved by the FDA, the European Medicines Agency, Australia’s Therapeutic Goods Administration, or any other regulator. It is being studied under an active Investigational New Drug (IND) application, and its only legal availability is through enrollment in an authorized clinical trial listed on ClinicalTrials.gov.
Everything in this article is a projection based on Eli Lilly’s publicly disclosed development plans and standard FDA review timelines — not a confirmed release date. Drug approval timelines routinely shift due to trial delays, requests for additional data, manufacturing inspections, or safety reviews. Treat every date below as an estimate, not a promise.
Why So Much Attention on Retatrutide’s Timeline?
Interest in retatrutide’s approval date is driven by its Phase 3 results, which have outperformed every currently approved weight-loss injectable. In the pivotal TRIUMPH-1 trial, reported in Eli Lilly’s May 21, 2026 press release, participants taking the 12 mg dose lost an average of 28.3% of body weight over 80 weeks — exceeding the ~22.5% seen with tirzepatide (marketed as Zepbound) and far surpassing the ~14.9% seen with semaglutide (marketed as Wegovy). For background on how retatrutide works and why it’s generating this level of interest, see our foundational guide to retatrutide.
Full Milestone Table: Retatrutide’s Path to Approval
| Milestone | Timeframe | Status |
|---|---|---|
| TRIUMPH-4 readout (obesity + knee OA) | Dec 11, 2025 | ✅ Complete |
| TRANSCEND-T2D-1 topline (type 2 diabetes) | March 19, 2026 | ✅ Complete |
| TRIUMPH-1 topline (pivotal obesity trial) | May 21, 2026 | ✅ Complete |
| TRANSCEND-T2D-1 Lancet publication | June 2026 | ✅ Complete |
| TRIUMPH-2 (obesity + type 2 diabetes) | Q3–Q4 2026 | ⏳ Ongoing |
| TRIUMPH-3 (obesity + cardiovascular disease) | Q3–Q4 2026 | ⏳ Ongoing |
| NDA submission | Q4 2026 | Anticipated |
| FDA acceptance for review | Q1 2027 | Projected |
| PDUFA date / potential approval decision | Late 2027 | Projected |
| Commercial launch | Q1–Q2 2028 | Projected |
Table compiled from the Eli Lilly TRIUMPH-1 press release (May 21, 2026), The Lancet (June 2026), and standard FDA review timelines. All future dates are projections, not confirmed regulatory commitments.
Our Top 3 · July 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
Understanding Each Stage
Completed Trial Milestones (as of July 2026)
Four major data readouts have already been reported:
- TRIUMPH-4 (Dec 11, 2025) — combined obesity and knee osteoarthritis trial, showing 28.7% weight loss and 75.8% pain reduction at the 12 mg dose.
- TRANSCEND-T2D-1 topline (March 19, 2026) — the type 2 diabetes trial’s initial results.
- TRIUMPH-1 topline (May 21, 2026) — the pivotal obesity trial, the single most important dataset for a general weight-management approval, showing 28.3% average weight loss at 80 weeks.
- TRANSCEND-T2D-1 full publication (June 2026) — peer-reviewed results published in The Lancet, confirming HbA1c reductions of up to 2.0 percentage points alongside weight loss of 11.5–16.8%.
Trials Still Underway
Two additional pivotal trials remain in progress as of mid-2026:
- TRIUMPH-2, evaluating retatrutide in people with obesity and type 2 diabetes, expected to read out in Q3–Q4 2026.
- TRIUMPH-3, evaluating retatrutide in people with obesity and cardiovascular disease, also expected in Q3–Q4 2026.
These trials matter because FDA submissions typically bundle safety and efficacy data across a drug’s full development program. Their completion is one of the final gating items before Eli Lilly can file its NDA.
NDA Submission — Q4 2026
A New Drug Application is the formal package a sponsor submits to the FDA requesting approval. It bundles all Phase 1–3 data, manufacturing information, proposed labeling, and safety monitoring plans. Eli Lilly has signaled it expects to file retatrutide’s NDA in the fourth quarter of 2026, shortly after the anticipated TRIUMPH-2 and TRIUMPH-3 readouts.
FDA Acceptance — Q1 2027
After submission, the FDA has 60 days to decide whether to formally accept the NDA for review (a step called “filing”). If accepted, the review clock officially starts. This is projected for the first quarter of 2027.
FDA Review Period: Standard vs. Priority Review
Once an NDA is accepted, the FDA applies one of two review tracks:
- Standard review: approximately 10 months from acceptance to a target decision date.
- Priority review: approximately 6 months, reserved for drugs that may offer significant improvements over existing therapies for serious conditions.
Given the magnitude of retatrutide’s weight-loss and glycemic data relative to approved alternatives, some analysts believe a priority review is plausible, though the FDA has not confirmed this designation. Under a standard review timeline starting Q1 2027, the target decision — known as the PDUFA date — would land in late 2027.
PDUFA Date and Potential Approval — Late 2027
The Prescription Drug User Fee Act (PDUFA) date is the FDA’s internal target date for completing its review and issuing a decision: approval, rejection, or a Complete Response Letter requesting more information. Analysts and Eli Lilly’s own public commentary point to a PDUFA date in late 2027 as the earliest realistic approval milestone.
Commercial Launch — Q1–Q2 2028
Even after FDA approval, there is typically a gap of a few months before a drug becomes broadly available at pharmacies, driven by manufacturing scale-up, distribution logistics, and (for injectable biologics) supply constraints that have affected the entire GLP-1 category. If retatrutide is approved on schedule in late 2027, a launch window of Q1–Q2 2028 is the current working projection.
Comparison: How Retatrutide’s Timeline Stacks Up
| Drug | NDA Filed | FDA Approved | Time from Pivotal Trial Data to Approval |
|---|---|---|---|
| Semaglutide (Wegovy) | 2020 | June 2021 | ~13 months |
| Tirzepatide (Zepbound) | 2022 | Nov 2023 | ~14 months |
| Retatrutide (projected) | Q4 2026 | Late 2027 (projected) | ~13 months (projected) |
Historical GLP-1 approval timelines suggest roughly 12–14 months from pivotal Phase 3 data to FDA approval, which is broadly consistent with retatrutide’s projected Q4 2026 NDA filing and late-2027 decision.
What Could Delay This Timeline?
Several factors could push these dates later:
- Unexpected safety findings in the still-pending TRIUMPH-2 or TRIUMPH-3 data
- FDA requests for additional analyses or a Complete Response Letter
- Manufacturing or supply chain issues, which have affected the broader GLP-1 category
- Changes in FDA staffing, prioritization, or policy
None of these are certainties, but they are the typical reasons drug approval timelines shift in either direction.
What This Means for Patients Today
Because retatrutide remains unapproved, there is no legal way to obtain a prescription for it, and it cannot be legally compounded — it has no USP/NF monograph and was not included in the FDA’s 2026 compounding reclassification, meaning 503A and 503B pharmacies cannot legally prepare it. The only legitimate way to access retatrutide before approval is enrollment in an ongoing clinical trial. If you want to understand your eligibility and the enrollment process, see our detailed guide to joining a retatrutide clinical trial. If you need a currently approved option, tirzepatide and semaglutide-based treatments like Ozempic remain available today by prescription.
Frequently Asked Questions
When will retatrutide be FDA approved?
There is no confirmed approval date. Based on Eli Lilly’s disclosed development plans, an NDA submission is anticipated in Q4 2026, with a possible FDA decision (PDUFA date) in late 2027 — but this remains a projection, not a guarantee.
Is retatrutide approved anywhere in the world?
No. As of July 2026, retatrutide is not approved by the FDA, the EMA in Europe, Australia’s TGA, or any other major regulatory body.
Will retatrutide get priority review from the FDA?
This has not been confirmed. Priority review (about 6 months) is possible given retatrutide’s trial results relative to existing treatments, but standard review (about 10 months) remains the base-case assumption until the FDA states otherwise.
Can the retatrutide approval timeline change?
Yes. Trial delays, requests for additional FDA data, or manufacturing issues could push the NDA filing, PDUFA date, or launch window later than currently projected.
What can I do while waiting for retatrutide approval?
The only legal way to access retatrutide before approval is through a clinical trial. Otherwise, FDA-approved options such as Zepbound, Wegovy, and Ozempic are available today by prescription.
Medical disclaimer: Retatrutide is an investigational drug not approved by the FDA or any other regulatory authority as of July 2026. It is available only through enrollment in authorized clinical trials. This article is for informational purposes only and does not constitute medical advice, endorsement, or a recommendation to obtain retatrutide outside of a registered clinical trial. Speak with your healthcare provider about currently approved weight-loss treatments. Content published by WeightLossInjections.com.
